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ABSTRACT: High-throughput mass spectrometry (MS)
glycomics is an emerging field driven by technological
advancements including sample preparation and data
processing. Previously, we reported an automated protocol
for the analysis of N-glycans released from plasma proteins
that included sialic acid derivatization with linkage-specificity,
namely, ethylation of α2,6-linked sialic acid residues and
lactone formation of α2,3-linked sialic acids. In the current study, each step in this protocol was further optimized. Method
improvements included minimizing the extent of side-reaction during derivatization, an adjusted glycan purification strategy and
mass analysis of the released N-glycans by ultrahigh resolution matrix-assisted laser desorption/ionization Fourier transform ion
cyclotron resonance MS. The latter resolved peak overlap and simplified spectral alignment due to high mass measurement
precision. Moreover, this resulted in more confident glycan assignments and improved signal-to-noise for low-abundant species.
The performance of the protocol renders high-throughput applications feasible in the exciting field of clinical glycomics.
Without compromising the value of genomic andtranscriptomic analyses it is widely acknowledged that
the complexity of the human body largely arises from
variations in protein expression as well as modifications
between cells, tissues and body fluids. In this context, mass
spectrometry (MS)-based proteomics has greatly contributed
to an understanding of cellular functions at a molecular level.1
Interestingly, in MS-based biomarker discovery efforts protein
glycosylation has often not been taken into account, albeit that
glycoproteins are key players in biological processes, such as
cell adhesion, endocytosis, receptor activation, signal trans-
duction, molecular trafficking, and clearance.2,3 Moreover,
glycosylation has proven to be reflective of (and in some cases
causal to) disease etiology. Notable examples include tumor
growth and metastasis, various inflammatory conditions and
autoimmune diseases, and congenital disorders of glycosyla-
tion.4,5 This neglect of glycans, and proteoforms in general, can
be rationalized from data complexity and technical chal-
lenges.6−8 In MS-based proteomics, database searches methyl-,
phosphate-, and acetyl-groups are accommodated by an exactly
defined mass difference, whereas glycans have different sizes
(monomeric to oligomeric) that moreover can be isobaric.
With regard to technical considerations, the applied analytical
methods require high-throughput (HT) platforms to study the
clinical relevance of protein glycosylation in large-scale studies,
as larger sample sizes have a higher risk of errors and
inconsistencies in sample preparation, leading to poor
repeatability.9
Multiple HT methods have been developed for proteo-
mics10,11 and glycomics9,12,21,13−20 purposes. For released N-
glycan analysis several HT methods are available: capillary
electrophoresis with laser-induced fluorescence detection (CE-
LIF),13,14 ultraperformance liquid chromatography with
fluorescence detection (UPLC-FLD),15,17 and matrix-assisted
laser desorption/ionization mass spectrometry (MALDI)-
MS.12,22 Some of these methods include LC runs, which
show a relatively lower throughput compared to MALDI-MS
and multiplexed CE-LIF. In addition, fluorescence detection is
often used, which has limitations for highly complex samples
due to potentially overlapping signals. Here we present a high-
performance mass spectrometric glycomics assay which
includes automated sample preparation and high resolution
mass spectrometry. This assay shows a range of advantages as
compared to other workflows and is based on our previous
plasma glycomics protocol that includes sialic acid derivatiza-
tion with linkage-specificity and a plate-based method for
glycan purification. High throughput: The assay can be run at
high throughput allowing the measurement of 576 samples
within 1 day, thereby making the analysis of large-scale clinical
cohorts possible. High coverage: 120 glycans were detected
from human plasma applying linkage-specific sialic acid
derivatization, 90 glycans whereof were consistently quantified.
High confidence identification: artifacts and contaminants
were minimized by optimizing the sample preparation.
Together with the high-resolution, high mass accuracy and
precision, this tackled issues regarding signal overlap and
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allowed confident glycan identification. High performance
relative quantification: Due to the automated and optimized
sample preparation including cotton thread microsolid phase
extraction tips, reproducible glycan profiles were obtained.
This novel high-performance workflow allows the robust
performance of large-scale clinical glycomics studies.
■ EXPERIMENTAL SECTION
Samples. Plasma standard (Visucon-F frozen normal
control plasma, pooled from 20 human donors, citrated and
buffered with 0.02 M HEPES) was purchased from Affinity
Biologicals (Ancaster, ON, Canada) and used for all
experiments.
Chemicals, Reagents, and Enzymes. Analytical grade
ethanol, sodium dodecyl sulfate (SDS), trifluoroacetic acid
(TFA), and potassium hydroxide (KOH) were obtained from
Merck (Darmstadt, Germany). Disodium hydrogen phosphate
dihydrate (Na2HPO4 × 2H2O), potassium dihydrogen
phosphate (KH2PO4), sodium chloride (NaCl), N,N′-
diisopropylcarbodiimide (DIC), N,N′-dicyclohexylcarbodii-
mide (DCC), 85% phosphoric acid (H3PO4), 50% sodium
hydroxide (NaOH), nonidet P-40 substitute (NP-40), 1-
hydroxybenzotriazole 97% (HOBt) and super-DHB (9:1
mixture of 2,5-dihydroxybenzoic acid and 2-hydroxy-5-
methoxybenzoic acid, sDHB) were purchased from Sigma-
Aldrich (Steinheim, Germany). 1-Ethyl-3-(3-(dimethylamino)-
propyl)carbodiimide (EDC) hydrochloride was obtained from
Fluorochem (Hadfield, UK), whereas recombinant peptide-N-
glycosidase F (PNGase F) was obtained from Roche
Diagnostics (Mannheim, Germany) and HPLC-grade acetoni-
trile (ACN) was purchased from Biosolve (Valkenswaard, The
Netherlands). Milli-Q water (MQ) was generated from a Q-
Gard 2 system (Millipore, Amsterdam, The Netherlands),
which was maintained at ≥18 MΩ.
Enzymatic N-Glycan Release. The enzymatic release of
N-glycans from plasma proteins was performed as previously
described, however using an acidified PBS buffer.12,23−25
Briefly, acidified PBS (pH 5.6) was prepared by adding 68
μL of 85% phosphoric acid to 9.93 mL of 5× PBS solution.
Then, 6 μL of plasma was added to 12 μL of 2% SDS and
incubated at 60 °C for 10 min. Next, 12.6 μL of freshly
prepared releasing mixture (6 μL of 4% NP-40, 6 μL of
acidified PBS, and 0.6 μL of PNGase F) was added, and the
samples were overnight incubated at 37 °C. Thus, prepared
samples were stored at −20 °C until further analysis and
measurement.
Automated Sample Preparation. The derivatization,
hydrophilic interaction liquid chromatography (HILIC)
purification, and MALDI-target plate spotting were performed
using an automated liquid handling platform as described in
Bladergroen et al.12 This platform allows for processing of 96
samples (i.e., one microtitration plate (MTP)) in a
simultaneous manner and can accommodate sequential
processing of six MTPs without interruption. The first plate
requires 1.5 h for processing, whereas the following ones each
add half an hour to the total processing time due to efficient
(overlapping) time scheduling.12 The ethyl esterification
derivatization was performed by adding 2 μL of released
glycan sample to 40 μL of ethyl esterification reagent (0.25 M
EDC with 0.25 M HOBt in ethanol) and incubating the
mixture for 1 h at 37 °C.24 Subsequently 40 μL of acetonitrile
was added and after 10 min the purification was started. In-
house assembled microtips used for cotton HILIC microtip
purification were prepared as follows: 3 mm cotton thread
(approximately 180 μg, Pipoos, Utrecht, Netherlands) was
placed into a 50 μL tip (clear CO-RE tip without filter,
Hamilton, Switzerland) by using tweezers. Then, a poly-
propylene porous frit (DPX Technologies, Columbia GA,
United States of America) was placed 18 mm above the tip
opening in order to prevent the cotton thread from floating
through the microtips during purification. The cotton HILIC
tips were three times prewetted with 40 μL of MQ water and
then conditioned with three times 40 μL of 85% ACN.
Subsequently the sample was loaded by pipetting the ethyl-
esterified sample 20 times up and down (40 μL per time). The
HILIC tips were washed three times with 40 μL of 85% ACN
containing 1% TFA, and three times with 40 μL of 85% ACN.
The purified N-glycans were eluted in 20 μL of MQ water by
pipetting five times up and down (pipet set at 15 μL). Next, 10
μL of purified sample was premixed with 5 μL of sDHB matrix
(5 mg/mL in 99% ACN with 1 mM NaOH) and 3 μL of the
mixture was spotted onto a MALDI target plate (800/384
MTP AnchorChip, Bruker Daltonics, Bremen, Germany). The
spots were allowed to dry in air, followed by MALDI-time-of-
flight (TOF)-MS measurement and subsequent MALDI-
FTICR-MS measurement of the exact same spot.
Sample Workup for Studying Adduct Formation. The
N-glycan release was performed three times in acidified PBS
(pH 5.6) and nine times in “regular” 5× PBS (pH 7.3). Ethyl
esterification was carried out according to the protocol
described above, however for the group of nine samples the
reaction was performed three times with three different
activating agents: 0.25 M EDC, 0.25 M DCC, or 0.25 M
DIC. The samples were subsequently purified with the manual
cotton HILIC solid phase extraction (SPE) microtips as
described previously,24,26 spotted onto a MALDI target plate
and allowed to dry in air.
MALDI-TOF-MS. MALDI-TOF-MS spectra were recorded
in reflectron positive mode on an UltrafleXtreme mass
spectrometer (Bruker Daltonics). The system was equipped
with a Smartbeam-II laser and operated by flexControl version
3.4 Build 135. Per sample 10 000 laser shots were collected at a
laser frequency of 1000 Hz. The spot was analyzed using a
random walking pattern of 200 shots per raster spot. Spectra
were recorded with an m/z-range of 1000−5000.
MALDI-FTICR-MS and MS/MS. MALDI-FTICR-MS
measurements were performed on a Bruker 15T solariX XR
FTICR mass spectrometer equipped with a CombiSource and
a ParaCell (Bruker Daltonics). The system was controlled by
ftmsControl version 2.1.0 and spectra were recorded with 1 M
data points (i.e., transient length of 2.307 s). A Bruker
Smartbeam-II Laser System was used for irradiation at a
frequency of 500 Hz using the “medium” predefined shot
pattern. Each MALDI-FTICR spectrum was generated in the
m/z-range from 1011.86 to 5000.00. At each raster 200 laser
shots were collected and each spectrum consisted of ten
acquired scans. The ParaCell parameters were as follows: the
DC bias RX0, TX180, RX180, and TX0 were 9.13, 9.20, 9.27,
9.20 V, respectively; the trapping potentials were set at 9.50
and 9.45 V and the excitation power and sweep step time at
55% and 15 μs. The transfer time of the ICR cell was 1.0 ms,
and the quadrupole mass filter was set at m/z 850. Collision-
induced dissociation (CID) experiments were performed in
the m/z-range 153.34−5000 with 512 k data points. The
quadrupole (Q1) was used from precursor ion selection with
an isolation window of 12 mass units. Fragments were
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generated using a collision energy of 75 V. DataAnalysis
Software 4.2 (Bruker Daltonics) was used for the visualization
and data analysis of MALDI-(CID)-FTICR spectra.
Method Repeatability. The repeatability of the method
was evaluated by performing the sample preparation and
measurements multiple times on three different days. On day 1
the process described in the section “automated sample
preparation” was repeated three times with 96 samples each
time and on day 2 and 3 the process was repeated once with 96
samples per day. From this data the intraplate, intraday, and
interday variation can be determined. The intraplate variation
was calculated over the total amount of spectra per plate. The
intraday variation was calculated over the total amount of
spectra from day 1 (plates 1−3) and the interday variation was
calculated over the total amount of spectra from all days
(plates 1−5).
Preprocessing of Mass Spectral Data. The MALDI-
TOF-MS spectra were transformed in text format (x,y) using
flexAnalysis 3.4 (Bruker Daltonics). The data transformation to
text format of the MALDI-FTICR-MS spectra was performed
with DataAnalysis 3.1 (Bruker Daltonics). With MassyTools
0.1.8.1, the text files were calibrated if at least five calibrants
showed a signal-to-noise (S/N) ratio of 9 or higher, which was
the case in all 480 MALDI-TOF-MS spectra and 479 out of
480 MALDI-FTICR-MS spectra. The list of calibration masses
is shown in the Supporting Information Table S-1. In addition,
the spectra showing less than (average of all spectra) minus 3
× (standard deviation) of the analyte area above S/N 9 were
excluded in the analysis (13 MALDI-TOF-MS spectra and 6
MALDI-FTICR-MS spectra).
In the obtained spectra, the m/z values corresponding to
163 glycan compositions including 19 “dummy signals” (as
defined in Table S-2) were integrated with a coverage of 95%
of the theoretical isotopic envelope per analyte. For the
MALDI-TOF-MS data an extraction window of 0.49 m/z-units
was applied, while for the MALDI-FTICR-MS spectra an
increasing mass window was used for increasing m/z values
(see Table S-3). Analyte curation was performed with multiple
quality criteria: the S/N of the analyte for the median of all
spectra had to be at least 6, the quality score for the
comparison of the theoretical and observed isotopic envelope
of the analyte had to be lower than 0.5 for the median of all
spectra and the PPM-error of the analyte had to be lower than
10 for the first quartile of all spectra. All dummy analytes were
excluded by these criteria. In addition, 64 signals were
excluded for further analysis in the MALDI-TOF-MS spectra
and 53 in the MALDI-FTICR-MS spectra. The complete list of
N-glycans included in the extraction is shown in Table S-4. In
this list also the observed glycan analytes that could not be
extracted because of lacking intensity or overlap with other
signals are displayed. For MALDI-TOF-MS and MALDI-
FTICR-MS, spectra these were 5 and 19 analytes, respectively.
Additionally, for 10 analytes only the first isotopic peak could
be used for analysis, due to overlap of the other isotopic peaks
with other signals.
The extracted area values for the selected glycans were
normalized to the sum of all areas for each spectrum separately.
In addition derived traits were calculated from single glycans
using R-Studio software with an in-house written script. The
exact calculations for these derived traits, including the
information on which glycans are involved in a certain trait,
are shown in Table S-5.
Per analyte and trait the average area, standard deviation
(SD) and relative standard deviation (RSD) were calculated.
In addition, the average RSD of the 25 most abundant glycans
was determined. These calculations were done for the
intraplate, intraday, and interday variation.
■ RESULTS AND DISCUSSION
Protocol Development. The initial plasma glycomics
protocol that includes a sialic acid derivatization method with
linkage-specificity was used as a starting point for the
development and optimization of a high performance assay.12
Method improvements included minimizing the extent of side-
reaction during derivatization, an adjusted glycan purification
strategy and mass analysis of the released N-glycans by
MALDI-FTICR. The benefits of MALDI-FTICR mass analysis
of the plasma glycome will be presented and compared to
MALDI-TOF readout. With these improvements the assay is
now suitable for HT studies with predefined quality
Figure 1. Annotated MALDI-FTICR-MS spectrum of released total plasma N-glycome, with the signals assigned as [M + Na]+ compositions. The
glycans were enzymatically released and subsequently ethyl esterified, cotton HILIC purified and spotted on a MALDI-target by the automated
pipetting platform. The linkages and positions of the monosaccharides are based on literature as linkage specific information cannot be extracted
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metrics.27,28 A resulting ultrahigh resolution glycan profile of
the improved and optimized protocol is exemplified in Figure
1. Here, released N-glycans were accurately identified up to
m/z-values higher than 4000. Moreover, high precision
measurement of mass differences allowed identification of a
byproduct as follows.
Identification of a Byproduct from Derivatization.
Upon careful inspection of the MALDI-based glycan profiles
(such as depicted in Figure 1), it was observed that satellites of
annotated glycans appeared with mass increases of +132.174 ±
0.002 and 357.205 ± 0.029 Da, respectively (averaged over
114 profiles for three different analytes). Previously, these were
explained as unidentified reducing end modifications or
ionization variants, namely at +132.19 and +357.18 Da of
each glycan signal.29 These signals only appear when the ethyl
esterification method is used, so it is likely that one of the
chemicals used in this reaction reacts with the glycan. In Figure
2A, the hypothesized reaction of EDC and other carbodiimides
with the reducing end of the glycan is illustrated. For this
reaction it is assumed that the hydrolysis reaction of the
glycosylamine after PNGase F release has not completed
before addition of the ethyl esterification reagent. The resulting
molecule matches the observed m/z-values when it is ionized
as [M + H]+. To further confirm this hypothesis, fragmentation
of the +132.19-signal of H5N4E2 at m/z 2434.002 was
performed and showed that the additional mass was indeed
located at the reducing end and ionized as a proton adduct
(Figure 2B and 2C).
The observed fragments (see also Figure S-1) match the
structure as it was proposed in Figure 2A. This reaction results
in a theoretical mass shift of 132.1763 m/z-units, which
matches the observed mass shift. To proof that it is truly an
addition of the complete EDC molecule, the reaction was also
performed with two carbodiimides with different side groups.
For these samples the glycan release was performed at regular
pH 7.3. The results of these experiments are shown in Figure
2D panel 1−3. The shift of the extra peaks corresponds exactly
to the mass differences between the different carbodiimides.
To test whether the artifact is linked to the presence of
glycosylamines, we performed the glycan release at slightly
acidic conditions, knowing that glycosylamines are sensitive to
acidic hydrolysis. The glycans from the sample in Figure 2D,
panel 4, were released with PNGase F in acidified PBS and
ethyl esterified with EDC as an activating reagent. In this
Figure 2. (A) Reaction scheme of the observed reaction of the reducing end glycosylamine with a carbodiimide activating reagent. Chemical
structures and reactions were drawn in Marvin (Marvin 17.26.0, ChemAxon). (B and C) MALDI-CID-FTICR-MS spectrum of EDC-linked
H5N4E2 selected at m/z 2434.002. For more fragmentation spectra, see Figure S-1. (D) MALDI-TOF-MS spectra of derivatized H5N4E2. In
panel D1−3 the observed m/z difference between the free reducing end glycan (H5N4E2 at m/z 2301.84) and the same glycan with the different
carbodiimides attached to the reducing end is shown. The difference in peak shift corresponds to the mass difference of the R-groups of the
different carbodiimides. For these samples, the glycan release was performed at regular pH 7.3. In panel D4 a spectrum is shown of a glycan release
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spectrum no signals corresponding to the byproduct were
visible. This is explained by the hydrolysis reaction that is
favored at lower pH. This adjustment of the pH of the glycan
release reaction prevents the presence of glycosylamines in the
subsequent ethyl esterification reaction. In addition, it is worth
noting that the signals at +357.205 Da also disappear from the
spectra when the glycan release is performed at lower pH. This
indicated that these satellites may indeed be linked to the
presence of glycosylamines. Interestingly, these peaks do not
change when using different carbodiimides, implying that the
additional mass originates from another source. Clearly, the
“removal” of these satellites of annotated glycans by perform-
ing the release in acidified PBS simplifies the MALDI-profiles.
It is furthermore stressed that the here applied FTICR-MS
read-out facilitates the identification of other, obviously
unwanted, satellite or unexplained signals. For example, in
MALDI-based analysis of glycans the potential loss of the
reducing end GlcNAc (−221.0899 Da or in the case of a core
fucosylation −367.1478 Da) should be taken into account, as
well as signals resulting from a 0,2A cross-ring fragmentation29
or a 2,4A cross-ring fragmentation of the reducing end
GlcNAc.29
Automated Cotton HILIC Purification. It was found that
our initial GHP plate-based HILIC-SPE method for glycan
purification (GHP plate, Pall AcroPrep Advance 96 Filter plate,
Pall Corporation, Ann Arbor, MI) suffered from batch-to-batch
differences for released glycans.12 Both the signal intensity in
the spectra and the number of glycans visible in the spectra
were decreasing over time. A clear explanation for this decrease
could not be traced and for that reason an alternative
purification method was added to the protocol. Here,
automated HILIC purification was performed with cotton
thread as the stationary phase that previously has been used in
manual purification protocols.24 For the automated method a
piece of cotton thread was put into a pipet tip and was kept in
place by capping it with a porous frit. These newly and in-
house prepared microtips enabled the application of cotton
HILIC tips in an automated pipetting platform.
Using the automated cotton HILIC tips for purification
instead of a GHP filter plate the spectral quality increased with
respect to the signal intensity and glycan coverage. Moreover,
using purification tips instead of a filter plate implies that there
is no need to have a vacuum manifold or centrifuge (for
elution) available on the pipetting platform. Furthermore, the
overall throughput of the protocol is increased.
Glycan Assignments. As the resolving power in MALDI-
FTICR-MS spectra is higher compared to MALDI-TOF
(ranging from 20 000 to 10 000 in TOF versus 100 000 to
50 000 in FTICR30), overlapping species in the glycan profiles
become visible (see top and middle panel of Figure 3). The
narrow peaks result in a higher peak capacity in the spectrum
and moreover are measured at higher precision compared to
MALDI-TOF-MS data. With suitable calibration of the
MALDI-FTICR-MS spectra (<5 ppm errors for calibrants),
the accuracy of the measurement increases to a level where the
measured m/z can give a strong indication of the
monosaccharide composition of the analyte. As a consequence,
fewer false assignments are made and annotations are of higher
confidence. In addition, the number of detected glycan signals
is increased due to the larger dynamic range of the MALDI-
FTICR-MS: signals with intensities near the limit of detection
in MALDI-TOF-MS spectra could not be included for analysis,
but the corresponding glycan signals in MALDI-FTICR-MS
spectra showed higher intensity and S/N ratio, which made it
possible to include these signals in the analysis. More details on
the observed and relatively quantified analytes in MALDI-
TOF-MS versus MALDI-FTICR-MS are found in Table S-4.
In the MALDI-TOF-MS spectra 86 glycan signals were
annotated of which 80 could be extracted for relative
quantification. For the MALDI-FTICR-MS spectra these
numbers were 112 and 91, respectively. From these
quantifiable glycans 76 were extracted from both MALDI-
TOF-MS and MALDI-FTICR-MS spectra, 15 glycan signals
were exclusively extracted in MALDI-FTICR-MS and 4 were
exclusively extracted in MALDI-TOF-MS spectra. It should be
noted that of these four MALDI-TOF-MS glycan signals (see
Table S-4) one (H7N6E4) was observed in MALDI-FTICR-
MS spectra, but due to overlap could not be quantified, see
Figure 3. The three remaining glycan signals did not have a
Figure 3. Resolving power of MALDI-FTICR-MS. In the top
MALDI-TOF-MS spectrum a single isotopic pattern is visible, while
in the middle MALDI-FTICR-MS spectrum there are two isotopic
patterns observed. In the lower MALDI-FTICR-MS spectrum the
glycan signal of H7N6E4 can be distinguished from an overlapping
signal, but could not be extracted for relative quantification.
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corresponding signal in MALDI-FTICR-MS spectra, in fact it
was observed that the isotopic pattern of these signals did not
correspond to glycan identities.
As a result of the higher resolving power of MALDI-FTICR-
MS measurements the glycan signals were annotated with
higher confidence. For most of the annotated glycans we
published in previous studies the current data corroborated
with proposed compositions. However, we also found a few
interesting exceptions. In both MALDI-TOF-MS and MALDI-
FTICR-MS, a signal was observed around m/z-value 3132.14
(see Figure 3). In previous MALDI-TOF-MS studies this
signal was often annotated as H6N5F1E3, a triantennary
glycan which matches all quality criteria of the data
preprocessing. However, in MALDI-FTICR-MS spectra not
one, but two partially overlapping signals are observed, as is
shown in Figure 3. One of these signals indeed matches the
mass of the triantennary glycan composition stated above, but
the other signal can very well be annotated as a signal
corresponding to the tetraantennary glycan H7N6F1L1E1. In
MALDI-TOF-MS, it seemed that the signal was coming from
one analyte, while the resolution of the MALDI-FTICR-MS
spectra show that this signal is actually made up from two
different glycan species. Notably there were also some cases in
which the previous annotation was proven wrong. For example,
a species previously assigned as H4N6F1E1 (m/z-value
2372.87) on the basis of TOF data12 is now considered to
be a byproduct or adduct from another glycan, because the
signal highly decreases when the glycan release is performed at
lower pH. In addition, there were some signals which in
MALDI-TOF-MS were annotated with some compositions,
such as H4N7E1, that are questionable in a biosynthetic
manner. Here the high resolution in combination with a good
calibration showed that the ppm error for this composition and
signal was much higher than for the other signals.
Repeatability of Glycan Relative Quantifications.
From the obtained MALDI-TOF-MS, as well as MALDI-
FTICR-MS spectra, the variation of the sample preparation
combined with the measurements was calculated for both
systems. The intraplate-, intraday-, and interday variation was
calculated for the glycan with the highest relative area
(H5N4E2) (see Table S-6) and averaged for the ten glycans
(specific compositions are shown in Table S-6) with the
highest relative area, which is shown in Figure 4. In this figure
also the variation of the 25 glycans with the highest relative
area is shown. The variation of all glycans is shown in Figure S-
2 and in addition the variation of the calculated derived traits is
shown in Figure S-3. From the information presented in Figure
4 and Table S-7 we can conclude that the variation of the
MALDI-TOF-MS and MALDI-FTICR-MS measurements is
similar to those reported previously: the variation of the most
abundant signal is found to be around 5%.12 For the ten most
abundant signals the average intraplate variation is 14.9% for
the MALDI-TOF-MS measurements, whereas for the MALDI-
FTICR-MS measurements this variation is only 9.0%. When
comparing the interday variation this slight difference is also
visible with 16.5% and 9.9% variation for the MALDI-TOF-MS
and MALDI-FTICR-MS measurements, respectively. This
shows that the variation in the MALDI-FTICR-MS measure-
ments is slightly lower than in the MALDI-TOF-MS
measurements.
■ CONCLUSION
The aim of the present research was to further develop and
improve our previous plasma glycomics protocol, which
includes linkage specific sialic acid derivatization, HILIC
Figure 4. Repeatability of the automated sample preparation method and MALDI-TOF-MS and MALDI-FTICR-MS measurements for the 25
most abundant glycan signals in MALDI-FTICR-MS. On day 1 the released glycan sample plate was processed three times (resulting in plate 1−3)
and on day 2 and day 3 the same sample plate was processed once (respectively resulting in plate 4 and plate 5). Error bars show standard
deviation. H = hexose, N = N-acetylhexosamine, F = deoxyhexose (fucose), L = lactonized N-acetylneuraminic acid (α2,3-linked), E = ethyl
esterified N-acetylneuraminic acid (α2,6-linked).
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purification, and MALDI measurement. In this study, the
occurrence of side-reactions during derivatization was
successfully prevented and a newly automated HILIC
purification method was included. Moreover, the measure-
ments were performed on a MALDI-FTICR-MS instrument,
providing ultrahigh resolution spectra with resulting higher
dynamic range and precision, which were proven to be
beneficial for the correct annotation and relative quantification
of the observed signals. These changes were made without
affecting the repeatability of the protocol. Taken together, the
improvements in the methods provide a time-efficient and
repeatable protocol with higher confidence identifications for
glycosylation analysis in clinical applications.
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